by ADRIAN MANZ | Oct 21, 2025 | The Doctor's Dose
Apple’s iPhone 17 Ignites Growth Ahead of Holiday Season By TraderInsight Editorial Team | October 20, 2025 The launch of the Apple iPhone 17 is fueling the company’s strongest smartphone growth since the Covid-19 boom, driven by its bold redesign, upgraded cameras,...
by ADRIAN MANZ | Oct 20, 2025 | The Doctor's Dose
Fed Rate Cut in October Is as Good as Done — December Is the Real Battleground The Federal Reserve appears locked in for another Fed rate cut in October 2025, with policymakers signaling near-unanimous support for a quarter-point reduction. Markets have already priced...
by ADRIAN MANZ | Oct 20, 2025 | The Doctor's Dose
AWS Outage 2025: What Broke, Who Felt It, and How Markets Reacted A major AWS outage 2025 event rocked the internet on Monday, taking down portions of Snapchat, Reddit, Roblox, the McDonald’s app, and disrupting Coinbase and United Airlines. Amazon Web Services...
by ADRIAN MANZ | Oct 17, 2025 | The Doctor's Dose
Barrick Mining: New Name, Copper Focus, and Investor Revival Ahead Barrick Mining, formerly known as Barrick Gold, has rebranded itself and changed its stock ticker from GOLD to B, marking a strategic shift that emphasizes its growing stake in the global copper...
by ADRIAN MANZ | Oct 14, 2025 | The Doctor's Dose
Polaris Stock Soars on Indian Motorcycle Sale — What It Means for Harley-Davidson TraderInsight • October 2025 • Industrials / Consumer Goods Deal at a Glance Polaris (PII) announced it will spin off its **Indian Motorcycle** business, with private equity firm...
by ADRIAN MANZ | Oct 14, 2025 | The Doctor's Dose
Dow Marks Biggest Comeback Since April as China Tensions Roil Markets The Dow Jones Industrial Average closed up +203 pts (+0.4%) after rebounding from an early slide of more than 600 pts, its most significant low-to-close reversal since April. The S&P 500 slipped...
by ADRIAN MANZ | Oct 13, 2025 | The Doctor's Dose
Why Tesla Stock Is a Must-Own in the Age of AI Tesla (NASDAQ: TSLA) surged 5.4% Monday to close at $435.90, rebounding from Friday’s sharp selloff. The move was fueled by a new bullish call from Melius Research, which initiated coverage with a Buy rating and a $520...
by ADRIAN MANZ | Oct 9, 2025 | The Doctor's Dose
Levi Strauss Raises Prices and Profits — But the Stock Sells Off Levi Strauss (NYSE: LEVI) delivered a clean earnings beat for the third quarter — stronger profit margins, solid revenue growth, and an upgraded outlook. Yet shares fell sharply in after-hours trading,...
by ADRIAN MANZ | Oct 8, 2025 | The Doctor's Dose
ICE’s $2 Billion Bet on Polymarket Could Bring Prediction Markets Into the Mainstream TraderInsight • October 2025 • Fintech, Crypto, Market Microstructure Focus keyphrase: ICE Polymarket prediction market Wall Street Meets the Betting Market Intercontinental Exchange...
by ADRIAN MANZ | Oct 8, 2025 | The Doctor's Dose
What the Hard-to-Borrow Warning on NNE Really Meant By Adrian Manz • TraderInsight When a stock suddenly appears on the hard-to-borrow list, veteran traders pay attention. That change in market microstructure often precedes volatility, signaling that borrowing shares...
